HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
HCW Biologics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
HCW Biologics's total debt was $6.56M at Jun 30, 2026. For fiscal 2025 it was $6.81M, up 7.8% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.81M | +7.8% |
| FY2024 | Dec 31, 2024 | $6.31M | +5188.8% |
| FY2023 | Dec 31, 2023 | $119.40K | -99.7% |
| FY2022 | Dec 31, 2022 | $38.27M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.56M | +2.2% |
| Q1 FY2026 | Mar 31, 2026 | $6.58M | +5.5% |
| Q4 FY2025 | Dec 31, 2025 | $6.81M | +7.8% |
| Q3 FY2025 | Sep 30, 2025 | $6.81M | +7.4% |
| Q2 FY2025 | Jun 30, 2025 | $6.42M | +5278.0% |
| Q1 FY2025 | Mar 31, 2025 | $6.23M | +5197.7% |
| Q4 FY2024 | Dec 31, 2024 | $6.31M | +6403.2% |
| Q3 FY2024 | Sep 30, 2024 | $6.34M | +9227.2% |
| Q4 FY2023 | Dec 31, 2023 | $119.40K | -99.7% |
| Q3 FY2023 | Sep 30, 2023 | $117.68K | – |
| Q2 FY2023 | Jun 30, 2023 | $97.10K | – |
| Q1 FY2023 | Mar 31, 2023 | $67.98K | – |
| Q4 FY2022 | Dec 31, 2022 | $38.27M | – |
See a number that looks wrong?